(NASDAQ: LTGO) Latigo Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.85%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.61%.
Latigo Biotherapeutics's earnings in 2026 is N/A.On average, 5 Wall Street analysts forecast LTGO's earnings for 2026 to be -$152,495,128, with the lowest LTGO earnings forecast at -$155,936,064, and the highest LTGO earnings forecast at -$146,886,203. On average, 5 Wall Street analysts forecast LTGO's earnings for 2027 to be -$162,300,801, with the lowest LTGO earnings forecast at -$179,326,474, and the highest LTGO earnings forecast at -$149,670,776.
In 2028, LTGO is forecast to generate -$215,499,397 in earnings, with the lowest earnings forecast at -$311,222,395 and the highest earnings forecast at -$155,239,921.